Provided by Tiger Fintech (Singapore) Pte. Ltd.

Crinetics Pharmaceuticals Inc.

33.31
+0.20000.60%
Pre-market: 32.43-0.8800-2.64%04:06 EDT
Volume:737.02K
Turnover:24.52M
Market Cap:3.10B
PE:-9.02
High:33.59
Open:32.98
Low:32.21
Close:33.11
Loading ...

BRIEF-Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
11 Apr

Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Apr

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation Of Marketing Authorization Application (MAA) And Orphan Drug Designation (ODD) For Paltusotine In Acromegaly

Reuters
·
28 Mar

Crinetics Pharmaceuticals Says EMA Validates Marketing Authorization Application for Acromegaly Drug

MT Newswires Live
·
28 Mar

Crinetics Pharmaceuticals Announces European Medicines Agency (Ema) Validation of Marketing Authorization Application (Maa) and Orphan Drug Designation (Odd) for Paltusotine in Acromegaly

THOMSON REUTERS
·
28 Mar

Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly

GlobeNewswire
·
28 Mar

U.S. RESEARCH ROUNDUP-Ashland, Connectone Bancorp, Neurocrine Biosciences

Reuters
·
26 Mar

BUZZ-Stifel initiates Crinetics Pharma with 'buy' on FDA approval prospects

Reuters
·
25 Mar

Stifel Initiates Crinetics Pharmaceuticals at Buy With $60 Price Target

MT Newswires Live
·
25 Mar

Crinetics Pharmaceuticals Initiated at Buy by Stifel

Dow Jones
·
25 Mar

BRIEF-Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Reuters
·
11 Mar

Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
11 Mar

BUZZ-Morgan Stanley initiates Crinetics with 'outperform' on catalyst rich 2025

Reuters
·
08 Mar

Crinetics Pharmaceuticals Inc : Morgan Stanley Assumes Coverage With Overweight Rating; Price Target $70

THOMSON REUTERS
·
07 Mar

Promising Pipeline and Strategic Initiatives Drive Buy Rating for Crinetics Pharmaceuticals

TIPRANKS
·
07 Mar

Crinetics Pharmaceuticals Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
01 Mar

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
01 Mar

Crinetics Pharmaceuticals Is Maintained at Market Outperform by Citizens Capital Markets

Dow Jones
·
28 Feb

Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

TD Cowen Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)

TIPRANKS
·
28 Feb